// App-Quantinova.ai

: TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Researchers

Presenter

  • Neeraj Agarwal

Principal Investigators

  • Joan Carles

  • Andre P. Fay

  • Nobuaki Matsubara

  • Daniel Heinrich

  • Cezary Szczylik

  • Ugo De Giorgi

  • Jae Young Joung

  • Peter C.C. Fong

  • Eric Voog

  • Robert J Jones

  • Neal D. Shore

  • Curtis Dunshee

  • Stefanie Zschaebitz

  • Xun Lin

  • Cynthia G. Healy

  • Nicola Di Santo

  • Fabian Zohren

  • Karim Fizazi

Medical Centers

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • National Cancer Center Hospital, Tokyo, Japan

  • Clinique Victor Hugo - Centre Jean Bernard, Le Mans, France

  • Auckland City Hospital, Auckland, New Zealand

  • Institute of Cancer Sciences, University of Glasgow and The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany

  • Institut Gustave Roussy, University of Paris Sud, Villejuif, France

  • PUCRS School of Medicine Grupo Oncoclínicas, Porto Alegre, MA, Brazil

  • European Health Center Otwock & Postgraduate Medical Education Center, Warsaw, Poland

  • Innlandet Hospital, Gjovik, Norway

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • National Cancer Center, Goyang-si, Korea

  • IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori", Meldola, Italy

  • Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT

  • Urological Associates of Southern Arizona, Tucson, AZ

  • Carolina Urologic Research Center, Myrtle Beach, SC

Locations

  • Brazil

  • Germany

  • Republic of South Korea

  • New Zealand

  • United Kingdom

  • Italy

  • France

  • Japan

  • Spain

  • Australia

  • Poland

  • Norway

  • United States

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Hormone receptor

Drug/Treatment

  • Enzalutamide

  • CB-7598

  • Talazoparib

  • Docetaxel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • NCT03395197

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved